ECOR
NASDAQelectroCore Inc.
News · 26 weeks40-50%
2025-12-142026-06-07
Mix3390d
- Other13(39%)
- SEC Filings10(30%)
- Insider8(24%)
- Earnings2(6%)
Latest news
25 items- PRFrontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without SurgeryROCKAWAY, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the review article, "Without getting under your skin: non-invasive stimulation activates the vagus nerve," has been accepted for publication in Frontiers in Neuroscience. Authored by Norianne Theresa Ingram, PhD; Colin Daniels, MD, MBA; Nina Riggins, MD, PhD; Jennifer R. Stevane, MD, FACS; and Peter S. Staats, MD, MBA; the article synthesizes decades of scientific evidence supporting the ability of cervical non-invasive vagus nerve stimulation (nVNS) to activate vagal pathways without surgical implantation. The review eval
- PRelectroCore to Present at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClubROCKAWAY, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be presenting at Planet MicroCap Las Vegas 2026 Powered by MicroCapClub being held at the Bellagio Resort & Casino in Las Vegas, NV. Joshua Lev, Interim President and CFO, will deliver a presentation and host one-on-one investor meetings throughout the conference. Planet MicroCap Las Vegas 2026 Powered by MicroCapClub Details: Dates: June 17 - 18, 2026Company Presentation: Wednesday, June 17 at 10:30 am PTLocation: Bellagio Resort & Casino, Las Vegas, NV Webcast: https://event.summitcast.com/view/bpjo3VVjZ25pp6SXpU
- INSIDERCFO and Interim President Lev Joshua S. sold $60,003 worth of shares (6,667 units at $9.00), decreasing direct ownership by 7% to 84,889 units (SEC Form 4)4 - electroCore, Inc. (0001560258) (Issuer)
- SECSEC Form 144 filed by electroCore Inc.144 - electroCore, Inc. (0001560258) (Subject)
- INSIDERDirector Errico Thomas J. bought $59,852 worth of shares (9,992 units at $5.99), increasing direct ownership by 3% to 360,071 units (SEC Form 4)4 - electroCore, Inc. (0001560258) (Issuer)
- INSIDERCFO and Interim President Lev Joshua S. sold $19,500 worth of shares (3,000 units at $6.50), decreasing direct ownership by 3% to 91,556 units (SEC Form 4) (tax liability)4 - electroCore, Inc. (0001560258) (Issuer)
- SECSEC Form 144 filed by electroCore Inc.144 - electroCore, Inc. (0001560258) (Subject)
- PRelectroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in FibromyalgiaROCKAWAY, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the publication of new clinical findings in JAMA Network Open titled, "Transcutaneous Electrical Nerve Stimulation and Pain With Movement in People With Fibromyalgia: A Cluster Randomized Clinical Trial." The study evaluated the use of a modified Quell device, an FDA-authorized nonpharmacological wearable stimulation device, when added to outpatient physical therapy ("PT") for people with fibromyalgia. The trial enrolled 384 participants [that completed baseline data collection], including 191 individuals in the PT-Quell group an
- PRelectroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026ROCKAWAY, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the LD Micro Invitational XVI Conference being held at the Luxe Sunset Boulevard hotel in Los Angeles, CA. Joshua Lev, Interim President and CFO, will deliver a presentation and host one-on-one meetings throughout the day. LD Micro Invitational XVI Conference Details: Date: Monday, May 18, 2026 Company Presentation: 10:30 am PT Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA Webcast: Click for Link For more information or to attend the conference, click here. About electroCore,
- SECSEC Form 10-Q filed by electroCore Inc.10-Q - electroCore, Inc. (0001560258) (Filer)
- SECelectroCore Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - electroCore, Inc. (0001560258) (Filer)
- PRelectroCore Announces First Quarter 2026 Financial ResultsFirst quarter 2026 net sales of $9.6 million, an increase of 43% over $6.7 million in the first quarter 2025 Net loss of $5.3 million with Adjusted EBITDA net loss improving 24% from prior-year period to $2.3 million Company to host a conference call and webcast today, May 6, 2026, at 4:30 pm EDT ROCKAWAY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced financial results for the first quarter ended March 31, 2026. The Company reported record quarterly revenue of $9.6 million, an increase of approximately 43% year-over-year, driven by continued growth in U.S. prescription sales in
- SECSEC Form SCHEDULE 13G filed by electroCore Inc.SCHEDULE 13G - electroCore, Inc. (0001560258) (Subject)
- SECSEC Form 144 filed by electroCore Inc.144 - electroCore, Inc. (0001560258) (Subject)
- PRelectroCore TAC-STIM™ Named National Semifinalist in National Safety Council Work to Zero ChallengeROCKAWAY, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that TAC-STIM™, its non-invasive vagus nerve stimulation (nVNS) product for human performance, has been named a national semifinalist in the 2026 Work to Zero Safety Innovation Challenge (2026 Challenge), an annual initiative led by the National Safety Council (NSC) to identify technologies that can help prevent workplace injuries and fatalities. The 2026 Challenge is focused on solutions that address workplace fatigue, a significant and often overlooked safety risk that can impair judgment, slow reaction time, and increase the
- PRelectroCore to Announce First Quarter March 31, 2026, Financial Results on Wednesday, May 6, 2026ROCKAWAY, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the first quarter ended March 31, 2026, after the close of the market on Wednesday, May 6, 2026. Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the details below: Wednesday, May 6, 4:30 PM EDTDial-In: (646) 931-3860Webinar ID: 856 5438 2775Passcode: 895430Registration Link: Click here to participate and ask questions on the call. About electroCore, Inc.electroCore, Inc. is a bioelectronic techn
- PRelectroCore to Present at the Market Movers Investor Summit on May 5, 2026ROCKAWAY, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the Market Movers Investor Summit at the historic Bank of New York. Joshua Lev, Interim President and CFO, will deliver a presentation and host one-on-one meetings throughout the day. Event Details: Date: Tuesday, May 5, 2026Company Presentation: 12:20 PM ETLocation: 48 Wall Street, New York, NY (The original Bank of New York) Request an invitation to attend at www.marketmoverssummit.com. Summary of Market Movers Investor Summit The 2026 Market Movers Investor Summit begins on May 4th with a
- SECSEC Form 144 filed by electroCore Inc.144 - electroCore, Inc. (0001560258) (Subject)
- SECSEC Form D filed by electroCore Inc.D - electroCore, Inc. (0001560258) (Filer)
- INSIDERSEC Form 4 filed by Goldberger Daniel S4 - electroCore, Inc. (0001560258) (Issuer)
- INSIDERSEC Form 4 filed by Fox Michael4 - electroCore, Inc. (0001560258) (Issuer)
- INSIDERSEC Form 3 filed by new insider Fox Michael3 - electroCore, Inc. (0001560258) (Issuer)
- PRelectroCore to Participate in the 25th Annual Needham Virtual Healthcare ConferenceROCKAWAY, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place virtually on April 15, 2026. Joshua Lev, Interim President and Chief Financial Officer, will host a company presentation at 2:15 pm ET and participate in one-on-one meetings throughout the day. DATE: April 15, 2026TIME: 2:15 pm ET Investors attending the conference who are interested in scheduling a meeting with management can do so by contacting their Needham representative, or by emailing ECOR Investor Relations at investors@electroco
- PRelectroCore Announces First Patient Enrollment in Investigator-Led Study of gammaCore™ nVNS for PTSDROCKAWAY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the enrollment of the first eight patients in a clinical study being conducted by Acacia Clinics in collaboration with the Vagus Nerve Society. As previously announced, the study is designed to evaluate the safety and effectiveness of electroCore's gammaCore™ non-invasive vagus nerve stimulation (nVNS) device as an adjunctive treatment for symptoms associated with PTSD. The study is expected to enroll up to 40 adult participants and will assess outcomes over a 12-week treatment period. The primary safety endpoint is the incide
- INSIDERSEC Form 4 filed by Lev Joshua S.4 - electroCore, Inc. (0001560258) (Issuer)
ECOR FAQ
7 questionsWhat does electroCore Inc. do?
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.Where does ECOR stock trade?
electroCore Inc. (ECOR) is listed on NASDAQ.What sector and industry is ECOR in?
electroCore Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did electroCore Inc. go public?
electroCore Inc. (ECOR) completed its IPO in 2018.What are analysts saying about ECOR?
electroCore Inc. has had 2 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy with a $275.00 price target on 2022-01-19. Recent price targets range from $275.00 to $300.00.What companies are similar to ECOR?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare ECOR side-by-side with any of them on Quantisnow.How can I track ECOR on Quantisnow?
Quantisnow aggregates electroCore Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ECOR to receive live email and push alerts on every new disclosure.